Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Lakefront Biotherapeutics NV | 119 |
| 2 | AbbVie Inc | 106 |
| 3 | Merck and Co Inc | 101 |
| 4 | Chiesi Farmaceutici SpA | 89 |
| 5 | Gilead Sciences Inc | 84 |
| 6 | Roche Holding AG | 80 |
| 7 | Sanofi SA | 74 |
| 8 | Takeda Pharmaceutical Co Ltd | 68 |
| 9 | GSK PLC | 67 |
| 10 | Bristol Myers Squibb Co | 51 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 2,758 |
| 2 | A61K | Medicinal preparations | 2,585 |
| 3 | C07D | Heterocyclic compounds | 1,359 |
| 4 | C07K | Peptides | 690 |
| 5 | A61M | Devices for introducing media into the body | 457 |
| 6 | Y02A | Climate change adaptation | 425 |
| 7 | G01N | Investigating / analysing materials | 285 |
| 8 | C07F | Organometallic compounds | 212 |
| 9 | C07B | General methods of organic chemistry | 173 |
| 10 | C12N | Microorganisms, enzymes | 153 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| HETEROCYCLIC KINASE INHIBITORS | 2010 | Takeda Pharmaceutical Co Ltd | 384 |
| HETEROCYCLIC COMPOUNDS AND USES THEREOF | 2011 | Takeda Pharmaceutical Co Ltd | 260 |
| CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | 2009 | Takeda Pharmaceutical Co Ltd | 278 |
| HETEROCYCLIC COMPOUNDS AND USES THEREOF | 2012 | Infinity Pharmaceuticals Inc | 192 |
| METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | 2012 | Gilead Sciences Inc | 187 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 38 |
| 2017 | 26 |
| 2018 | 27 |
| 2019 | 15 |
| 2020 | 24 |
| 2021 | 12 |
| 2022 | 9 |
| 2023 | 12 |
| 2024 | 14 |
| 2025 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Jadwiga A. Wedzicha | Imperial College London | 11 |
| 2 | Nicolás Roche | Université Paris Cité | 9 |
| 3 | Robert Fogel | Novartis (United States) | 8 |
| 4 | Paul Dorinsky | Research Triangle Park Foundation | 7 |
| 5 | Neil Barnes | London Chest Hospital | 7 |
| 6 | Huib A.M. Kerstjens | University of Groningen | 7 |
| 7 | Kenneth R. Chapman | University of Toronto | 7 |
| 8 | Paul Jones | St George's, University of London | 6 |
| 9 | Hao‐Chien Wang | National Taiwan University Hospital | 6 |
| 10 | Melissa Roberts | Lovelace Clinic Foundation Research | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial | 2016 | 889 | Asthma and respiratory diseases |
| Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD | 2016 | 879 | Asthma and respiratory diseases |
| Effectiveness of Fluticasone Propionate and Salmeterol Combination Delivered via the Diskus Device in the Treatment of Chronic Obstructive Pulmonary Disease | 2002 | 508 | Asthma and respiratory diseases |
| Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD | 2015 | 330 | Asthma and respiratory diseases |
| Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study | 2012 | 317 | Asthma and respiratory diseases |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Adoair?
Which organizations hold the most patents related to Adoair?
What is the trend in patent filings for Adoair over the past decade?
Which author has published the most papers on Adoair and what is their affiliation?
What are the primary patent classification categories associated with Adoair?